Experimental Adjuvant Chemotherapy: An Overview

  • H. E. Skipper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 103)


By way of introduction, I will indicate in some detail what the key words in my assigned title mean to me.


Adjuvant Chemotherapy Lewis Lung Carcinoma Local Surgery Tumor Stem Cell Surgical Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Carter SK (1984) Adjuvant chemotherapy in osteogenic sarcoma: the triumph that isn’t. J Clin Oncol 2:147–148PubMedGoogle Scholar
  2. De Vita VT (1984) Opening comments: only if you believe in magic. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer IV. Grune and Stratton, Orlanda, pp 3–16Google Scholar
  3. Goldie JH, Coldman AJ (1983) Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep 67: 923–931PubMedGoogle Scholar
  4. Goldie JH, Coldman AJ, Gudauskas GA (1982) Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66: 439–449PubMedGoogle Scholar
  5. Griswold DP Jr (1972) Consideration of the subcutaneously implanted B16 malanoma as a screening model for potential anticancer agents. Cancer Chemother Rep 3: 315–324Google Scholar
  6. Griswold DP Jr (1975) The potential for murine tumor models in surgical adjuvant chemotherapy. Cancer Chemother Rep 5: 187–204Google Scholar
  7. Griswold DP Jr, Schabel FM Jr, Corbett TH, Dykes DJ (1981) Concepts for controlling drug-resistant tumor cells. In: Fidler IF, White RJ (eds) Design of models for testing cancer therapeutic agents. Van Nostrand Reinhold, New York, pp 215–224Google Scholar
  8. Hill RP, Stanley JA (1975) The response of hypoxic B16 melanoma cells to in vivo treatment with chemotherapeutic agents. Cancer Res 35: 1147–1153PubMedGoogle Scholar
  9. Skipper HE (to be published) Laboratory models: some historical perspective. Cancer Treat Rep (Special Symposium Issue: Laboratory models and clinical cancer)Google Scholar
  10. Skipper HE (1985) What phenomena are primarily responsible for cancers being classified as responsive, refractory or very refractory to chemotherapy? Southern Research Institute, Birmingham, pp 201–203 (Booklet 2)Google Scholar
  11. Skipper HE, Schabel FM Jr (1982) Quantitative and cytokinetic studies in experimental tumor systems. In: Holland JF, Frei E III (eds) Cancer medicine, 2nd edn. Lea and Febinger, Philadelphia, pp 663–685Google Scholar
  12. Skipper HE, Schabel FM Jr (1984) Tumor stem cell heterogeneity: implications with respect to classification of cancers by chemotherapeutic effect. Cancer Treat Rep 68: 43–61PubMedGoogle Scholar
  13. Skipper HE, Simpson-Herren L (1985) Relationship between tumor stem cell heterogeneity and responsiveness to chemotherapy. In: De Vita VT, Hellman J, Rosenberg SA (eds) Important advances in oncology 1985. Lippincott, Philadelphia, pp 63–77Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • H. E. Skipper
    • 1
  1. 1.Southern Research InstituteSouth, BirminghamUSA

Personalised recommendations